What is Leerink Partnrs' Estimate for Medpace Q2 Earnings?

Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) - Equities research analysts at Leerink Partnrs raised their Q2 2025 earnings per share (EPS) estimates for Medpace in a research note issued to investors on Tuesday, July 8th. Leerink Partnrs analyst M. Cherny now anticipates that the company will post earnings of $2.93 per share for the quarter, up from their prior forecast of $2.76. Leerink Partnrs has a "Hold" rating on the stock. The consensus estimate for Medpace's current full-year earnings is $12.29 per share. Leerink Partnrs also issued estimates for Medpace's Q4 2025 earnings at $3.11 EPS and FY2028 earnings at $15.92 EPS.

A number of other research analysts have also issued reports on the company. Mizuho lowered their target price on Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a report on Wednesday, April 9th. Leerink Partners started coverage on Medpace in a research note on Monday, March 24th. They issued a "market perform" rating and a $330.00 price target on the stock. Robert W. Baird dropped their price target on Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 23rd. TD Cowen cut Medpace from a "buy" rating to a "hold" rating and dropped their price target for the stock from $370.00 to $328.00 in a research note on Monday, April 14th. Finally, Truist Financial dropped their price target on Medpace from $333.00 to $300.00 and set a "hold" rating on the stock in a research note on Wednesday, April 23rd. Twelve research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Medpace currently has an average rating of "Hold" and an average price target of $344.82.

Medpace Trading Down 1.4%

NASDAQ:MEDP traded down $4.74 during mid-day trading on Thursday, reaching $323.50. 293,644 shares of the stock were exchanged, compared to its average volume of 377,752. The business has a fifty day moving average price of $305.61 and a 200 day moving average price of $318.86. The firm has a market capitalization of $9.30 billion, a PE ratio of 24.69, a PEG ratio of 5.94 and a beta of 1.47. Medpace has a 1-year low of $250.05 and a 1-year high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.06 by $0.61. The firm had revenue of $558.57 million for the quarter, compared to analyst estimates of $528.38 million. Medpace had a return on equity of 54.36% and a net margin of 19.31%. During the same period in the previous year, the company earned $3.20 earnings per share.

Insider Activity

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of Medpace stock in a transaction dated Thursday, April 24th. The stock was sold at an average price of $301.82, for a total transaction of $516,715.84. Following the completion of the sale, the director directly owned 2,998 shares in the company, valued at $904,856.36. The trade was a 36.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 20.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Medpace

Several institutional investors and hedge funds have recently added to or reduced their stakes in MEDP. Vanguard Group Inc. lifted its holdings in shares of Medpace by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 2,570,770 shares of the company's stock worth $854,087,000 after buying an additional 25,704 shares during the last quarter. Invesco Ltd. grew its position in Medpace by 9.4% in the first quarter. Invesco Ltd. now owns 1,186,768 shares of the company's stock valued at $361,596,000 after acquiring an additional 102,015 shares during the period. Wasatch Advisors LP grew its position in Medpace by 3.1% in the fourth quarter. Wasatch Advisors LP now owns 936,842 shares of the company's stock valued at $311,247,000 after acquiring an additional 28,161 shares during the period. Mawer Investment Management Ltd. bought a new stake in Medpace in the first quarter valued at $212,131,000. Finally, Geode Capital Management LLC grew its position in Medpace by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 656,130 shares of the company's stock valued at $218,031,000 after acquiring an additional 28,076 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.